Novacor upgrade
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart will begin shipping an upgraded version of the left-ventricular assist device in the U.S. and Canada by the end of March, the company notes in a Jan. 7 release announcing FDA approval of the enhancements. Already approved in Canada and Europe, improvements include quieter pump operation, a smaller, longer-lasting battery and a smaller, quieter battery charger, according to the firm. Novacor is FDA-approved as a bridge to transplant, and will be the subject of a 250 to 300-patient destination therapy trial this year (1"The Gray Sheet" Nov. 10, 2003, p. 39)...
You may also be interested in...
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.